Table of Contents
Key Takeaways:
Amyloid plaques are a hallmark of Alzheimer's disease, forming up to 20 years before symptoms appear, making early biological intervention a growing area of scientific interest.
Nattokinase shows promise in lab and animal studies, with findings suggesting it may degrade amyloid proteins and support blood-brain barrier function, but no human clinical trials have confirmed these effects yet.
Nattokinase is not a treatment for Alzheimer's or cognitive decline. It's a dietary supplement with blood-thinning properties. Anyone considering it should consult a physician, especially if taking anticoagulants.
Amyloid plaques are protein accumulations strongly associated with Alzheimer's disease and age-related cognitive decline, making them a major focus of neuroscience research.
Researchers are exploring whether naturally derived compounds may interact with biological pathways involved in healthy aging. Among those compounds is nattokinase, an enzyme derived from the traditional Japanese fermented soybean food natto.
While emerging research has generated interest in nattokinase and brain health, it is important to understand the current state of the science. The findings so far are intriguing, but they do come with real limitations that are worth understanding before drawing conclusions. The most promising findings come from laboratory and animal studies.
What Are Amyloid Plaques?
Amyloid plaques are clusters of beta-amyloid proteins that accumulate between nerve cells in the brain.
That may sound highly technical, but the underlying process is simpler than it seems. Beta-amyloid is a naturally occurring protein fragment. Under normal circumstances, the body is able to naturally clear these protein fragments before they become problematic.
If the body cannot successfully eliminate the protein fragments, beta-amyloid can begin to accumulate and stick together, forming larger deposits known as plaques. These plaques are considered one of the hallmark features of Alzheimer's disease.
Researchers believe amyloid buildup may contribute to:
Inflammation in the brain
Disruption of neuron communication
Oxidative stress
Changes in brain structure over time
Here's what makes this particularly relevant to early intervention: amyloid accumulation may begin decades before symptoms appear. The most recent research suggests amyloid plaques can start forming 20 years or more before noticeable cognitive changes develop.
This long timeline is one reason scientists are increasingly focused on early biological processes involved in cognitive aging.
Why Is Cognitive Aging Research Accelerating?
The need for a better understanding of cognitive aging has never been greater. More than 55 million people worldwide are currently living with dementia, and that number is expected to increase as populations age.
While researchers continue investigating the causes of cognitive decline, there is growing interest in biological pathways that may contribute to the process.
Areas receiving increased attention include:
Vascular health
Inflammation
Oxidative stress
Blood-brain barrier function
Protein aggregation
Enzymatic activity involved in protein breakdown
Nattokinase is a proteolytic enzyme, meaning it can break down certain proteins. This characteristic has led researchers to investigate whether nattokinase may interact with amyloid proteins under experimental conditions. These investigations remain largely preclinical.
What Does the Research Say About Nattokinase and Amyloid Plaques?
Several studies have examined whether nattokinase can interact with amyloid proteins or influence cognitive markers in laboratory and animal models.
These findings are interesting, but they should be interpreted cautiously because they do not demonstrate effects in humans.
Hsu et al. (2009)
One of the foundational studies in this area came from Hsu and colleagues in 2009. Researchers reported that nattokinase demonstrated the ability to degrade amyloid fibrils under laboratory conditions. This finding generated interest because amyloid fibrils are one of the structural components involved in plaque formation.
It’s vital to consider that laboratory experiments do not necessarily predict what will occur inside the human brain.
Fadl et al. (2013)
A later animal study examined oral nattokinase supplementation in a rat model of Alzheimer's-like pathology. Researchers observed reductions in amyloid accumulation within the hippocampus, a brain region heavily involved in learning and memory.
The results suggested potential biological activity, but because the research was conducted in animals, the findings cannot be directly applied to humans.
Tanikawa et al. (2024)
A 2024 animal study provided some of the most attention-grabbing findings to date. Researchers reported that oral nattokinase administration reduced amyloid plaque burden by approximately 37% in a rat model over a 10-week period. The study also reported improvements in measures related to brain structure.
These findings contributed to growing scientific interest in nattokinase's potential interactions with amyloid proteins. That said, this was an animal study. Human clinical confirmation does not yet exist, and that's the central limitation of everything discussed here.
Brain Research (2025)
Research published in Brain Research in 2025 explored nattokinase's potential role in supporting blood-brain barrier integrity in preclinical models.
The blood-brain barrier acts as a protective filter between circulating blood and brain tissue — think of it as kind of a checkpoint that decides what gets in and what stays out. Dysfunction of this barrier has been implicated in multiple neurodegenerative conditions.
Researchers observed findings suggesting nattokinase may support blood-brain barrier function and cognitive performance in experimental models.
While these results are promising from a scientific perspective, they remain preclinical and require human validation.
What We Know So Far
Current evidence suggests nattokinase may interact with amyloid-related pathways in laboratory and animal settings.
It's worth being clear about what the research does not yet show:
Human clinical trials examining amyloid plaque reduction do not yet exist.
No published studies show nattokinase improves cognition in people with Alzheimer's disease.
Researchers do not yet know whether findings seen in animals translate to humans.
Additional safety and efficacy research is needed.
Science is emerging, but not fully established. Researchers need more time and study opportunities to understand the potential of nattokinase.
The USC NAPS Trial
The ongoing USC Nattokinase Atherothrombotic Prevention Study (NAPS) is a randomized clinical trial primarily focused on cardiovascular outcomes, but cognition has been included as a secondary area of interest.
Researchers hope the study may provide valuable information about nattokinase's broader effects on healthy aging. Human research is underway, and future findings will be an important next step in determining whether the encouraging preclinical evidence translates to real-world benefit for people.
What Should You Keep in Mind About Nattokinase?
Some people exploring additional ways to support cardiovascular and cognitive wellness consider nattokinase as part of a broader healthy lifestyle.
Interest in nattokinase has grown partly because of cardiovascular research such as the 2022 study by Chen et al., which followed 1,062 participants receiving 10,800 FU of nattokinase daily. The study focused on cardiovascular outcomes rather than cognitive health, but it contributed to broader scientific interest in nattokinase and healthy aging.
It is also important to remember that nattokinase has blood-thinning properties. Individuals taking anticoagulants, antiplatelet medications, or aspirin should speak with their physician before considering nattokinase supplementation.
Always speak with your doctor. Brain health is a complex topic that involves genetics, lifestyle, cardiovascular health, sleep quality, nutrition, and many other factors. If you are concerned about cognitive aging, memory changes, dementia risk, or Alzheimer's disease, discuss your concerns with a qualified healthcare professional.
This is especially important if you:
Take blood-thinning medications
Have a bleeding disorder
Have been diagnosed with cognitive impairment
Are considering adding new supplements to your routine
While the research surrounding nattokinase and amyloid plaques is intriguing, it's still too early to make a definitive judgment relating to its full clinical efficacy and support potential.
The Bottom Line on Nattokinase and Brain Health
Interest in amyloid plaques and cognitive aging continues to drive new areas of scientific research, including studies involving enzymes such as nattokinase. Laboratory and animal studies have produced encouraging findings suggesting nattokinase may interact with amyloid-related pathways, support blood-brain barrier function, and influence markers associated with cognitive aging.
These findings remain preclinical. Human clinical studies demonstrating benefits for amyloid plaques, Alzheimer's disease, or cognitive decline do not yet exist.
For now, nattokinase is best understood as an area of emerging scientific interest that’s worth watching, but isn’t yet a proven cognitive health intervention. As additional human research becomes available, scientists will gain a clearer understanding of its potential role in healthy aging.
If you are interested in supporting long-term brain health, speak with your physician about evidence-based strategies and whether any dietary supplements are appropriate for you.
FAQs
Can nattokinase dissolve amyloid plaques in humans?
Current research showing nattokinase's ability to break down amyloid comes from laboratory and animal studies. No published clinical trials have confirmed this effect in humans yet. The science is promising, but still early, and human studies are underway.
Is nattokinase safe for brain health?
Nattokinase has a well-established safety record in cardiovascular research. However, because it has blood-thinning properties, people on anticoagulants (warfarin, DOACs) or aspirin should consult their physician before use. Always discuss any new supplement with your doctor, especially for conditions affecting the brain.
Should I take nattokinase instead of Alzheimer's medication?
No. Nattokinase is a dietary supplement and is not a replacement for any prescribed medication. If you or a loved one has been diagnosed with Alzheimer's disease or cognitive impairment, follow your physician's treatment plan. Toku Flow is not designed or intended to treat, prevent, or slow any form of dementia.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Keep out of reach of children. Consult with your physician before use if you are pregnant, nursing, have a medical condition, or taking anticoagulants. Discontinue use and consult with your health care professional if you experience any adverse reaction to this product.
Sources:
Biomarker Changes during 20 Years Preceding Alzheimer’s Disease | New England Journal of Medicine
Amyloid-degrading ability of nattokinase from Bacillus subtilis natto | PubMed
Study Details | NCT02080520 | Nattokinase Atherothrombotic Prevention Study | ClinicalTrials.gov
